Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program

BACKGROUND: Traditionally, clinical trials evaluating effects of a new therapy with creatinine-based renal end points use doubling of serum creatinine (equivalent to a 57% eGFR reduction), requiring large sample sizes. METHODS: To assess whether eGFR declines <57% could detect canagliflozin’s eff...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Am Soc Nephrol
Auteurs principaux: Oshima, Megumi, Neal, Bruce, Toyama, Tadashi, Ohkuma, Toshiaki, Li, Qiang, de Zeeuw, Dick, Heerspink, Hiddo J.L., Mahaffey, Kenneth W., Fulcher, Gregory, Canovatchel, William, Matthews, David R., Perkovic, Vlado
Format: Artigo
Langue:Inglês
Publié: American Society of Nephrology 2020
Sujets:
Clinical Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7609006/
https://ncbi.nlm.nih.gov/pubmed/32694216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019121312
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires